Michael J. Gray
About
In The Last Decade
Michael J. Gray
109 papers receiving 6.1k citations
Peers
Comparison fields: 5 of 145
- Molecular Biology 3.0k
- Oncology 1.6k
- Cancer Research 887
- Immunology 832
- Epidemiology 752
Countries citing papers authored by Michael J. Gray
This map shows the geographic impact of Michael J. Gray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Gray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Gray more than expected).
Fields of papers citing papers by Michael J. Gray
This network shows the impact of papers produced by Michael J. Gray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Gray. The network helps show where Michael J. Gray may publish in the future.
Co-authorship network of co-authors of Michael J. Gray
This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Gray. A scholar is included among the top collaborators of Michael J. Gray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Gray. Michael J. Gray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 17 | |
| 3 | 2 | |
| 4 | 1 | |
| 5 | 9 | |
| 6 | 7 | |
| 7 | 16 | |
| 8 | 20 | |
| 9 | 22 | |
| 10 | 11 | |
| 11 | 107 | |
| 12 | 21 | |
| 13 | 44 | |
| 14 | 51 | |
| 15 | A monoclonal antibody targeting the human urokinase plasminogen activator receptor (uPAR) combined with bevacizumab inhibits the growth of colon cancer metastases in the liver: Differential effects mediated by tumor burden. | 2 |
| 16 | 34 | |
| 17 | Interleukin-8 is regulated by a Src/STAT3 pathway in pancreatic adenocarcinoma cells that is NF-κB independent | 1 |
| 18 | 103 | |
| 19 | Neuropilin-1, a novel vascular endothelial growth factor receptor, promotes chemoresistance in pancreatic cancer cell lines | 1 |
| 20 | 14 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.